Table 1.
Treatment Intervention and PB Collection
| Treatment Day | Day of the Week | Regular Cycle GM-CSF (μg/m2) | Cycle 4 GM-CSF (μg/m2)* | Antibody 3F8 | PB Collection† |
|---|---|---|---|---|---|
| −5 | Wednesday | 250 SC | 250 SC | ||
| −4 | Thursday | 250 SC | 250 SC | ||
| −3 | Friday | 250 SC | 250 SC | ||
| −2 | Saturday | 250 SC | 250 SC | ||
| −1 | Sunday | 250 SC | 250 SC | ||
| 0 | Monday | 250 SC | 250 IV | IV | First (day 0) collection‡ |
| 1 | Tuesday | 250 SC | 250 IV | IV | |
| 2 | Wednesday | 500 SC | 500 IV | IV | |
| 3 | Thursday | 500 SC | 500 IV | IV | |
| 4 | Friday | 500 SC | 500 IV | IV | Second (day 4) collection |
Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IV, intravenous; PB, peripheral blood; SC, subcutaneous.
*
The first 56 patients on protocol received IV GM-CSF on days 0 through 4 of treatment cycle 4; 35 of these patients had adequate blood from both cycle 1 and cycle 4 for activation marker analysis.
†
Both PB samples were collected on site for immediate marker analyses.
‡
This sample was not collected on day −5, when GM-CSF was started usually at home or at home institutions because activation markers of neutrophils are labile and would likely be affected by storage and long-distance transport.